Dangerous Drugs: Fluoroquinolone Side Effects
Posted on December 2nd, 2013 by Oddo & Babat, P.C.
Used to treat mild to moderate bacterial infections, fluoroquinolones are among the most highly prescribed medications in the United States. When 33 year old Manhattan resident and Website Manager for the City College of New York Lloyd Balch sought medical attention for a fever and cough in April 2013, his doctor deduced from a chest […]
Antipsychotics Prescribed For Elderly Patients
Posted on November 25th, 2013 by Oddo & Babat, P.C.
The world’s eighth largest drug manufacturer, Johnson & Johnson, agreed to pay as much as $2.2 billion earlier this month to settle US probes into the marketing of antipsychotic drugs – including Risperdal – to older adults, children and the disabled. According to a New York Times article The Justice Department has determined that the company promoted […]
Type 2 Diabetes Risk: Antipsychotic Drugs and Children
Posted on October 23rd, 2013 by Oddo & Babat, P.C.
The use of second generation antipsychotic drugs (SGAs) appears to increase the risk of Type 2 diabetes in children, according to a 2001-2008 study by the Agency for Healthcare Research and Quality. While it was previously known that SGAs could double adult users’ chances of developing diabetes, the study suggests that children who are prescribed […]
Effectiveness and Reliability of the Drugs Presently Prescribed to Treat Hypothyroidism
Posted on August 26th, 2013 by Oddo & Babat, P.C.
According to a recent publication in the Wall Street Journal, some sufferers of hypothyroidism and several associated activist organizations are calling for more thorough screening tests and more effective treatment of the condition. Though studies regarding alternative therapies and medications show conflicting results, Michelle Bickford, the 36 year old founder of the advocacy group, ThyroidChange, […]
U.S. Department of Justice Releases Details of Rapamune Kidney Transplant Drug Settlement Case against Wyeth Pharmaceuticals
Posted on July 31st, 2013 by Oddo & Babat, P.C.
The marketing and sales practices of major pharmaceutical companies has been under scrutiny in the last few years. This week, the U.S. Justice Department announced that drug maker Wyeth Pharmaceuticals has agreed to a $490.9 million settlement for criminal and civil liability charges in connection with improperly marketing Rapamune, the kidney transplant drug. Wyeth Pharmaceuticals […]
Prescription Drug Errors
Posted on July 26th, 2013 by Oddo & Babat, P.C.
A good level of trust between a patient and doctor is mutually beneficial. It ensures the doctor can provide accurate, sufficient treatment and gives the patient peace of mind. In most cases, medical professionals live up to expected standards, treating patients with timely, thorough care and prescribing appropriate medications.
Glass Particles May Be Found in Generic Lipitor
Posted on November 30th, 2012 by Oddo & Babat, P.C.
According to a November 29 article by Katie Thomas in The New York Times, Ranbaxy Pharmaceuticals has stopped producing its generic version of Lipitor, pending investigation into the possibility of small glass particles being found in pills. The Food and Drug Administration announced the halt earlier that day. The FDA claims they have not received […]
How Much Legal Authority Does the FDA Have, and Use in Regulating Drug Compounding?
Posted on October 30th, 2012 by Oddo & Babat, P.C.
Legal experts are engaged in a new debate over the Food and Drug Administration’s authority of the drug compounding industry and perhaps their failure to use it. The recent outbreak of meningitis and the shutdown of Massachussets-based New England Compunding Center have again surfaced this issue with law makers and it is raising the question […]
FDA May Take Action Against Johnson & Johnson
Posted on June 1st, 2010 by Oddo & Babat, P.C.
The New York Times (5/28, B1, Singer) reports that McNeil Consumer Healthcare, the division of Johnson & Johnson that recalled millions of bottles of liquid children’s Tylenol, “may face criminal penalties, product seizures, or other sanctions, an official from the Food and Drug Administration said Thursday.” At a Congressional hearing yesterday, the principal deputy commissioner […]
Senate Committee Links Diabetes Drug Avandia to Heart Attacks, Death
Posted on February 24th, 2010 by Oddo & Babat, P.C.
On February 20, 2010 the New York Times carried a front-page story reporting that hundreds of patients taking the controversial diabetes medicine, Avandia (rosiglitazone), needlessly suffered heart attacks and heart failure each month, according to confidential governmental reports. The Wall Street Journal (Monday, 2/22), reported that a Senate Finance Committee concluded that Glaxo was aware […]